Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mainwaring

Showing results (431-440 of 465) with videos related to

Pageof 47
Sort By:
The Oncologist|April 10, 2020
Exclusion of Men from Randomized Phase III Breast Cancer Clinical TrialsKelsey L Corrigan, Walker Mainwaring, Austin B Miller, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2015
A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancerRebecca L Prue, Frank Vari, Kristen J Radford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerE G Chiorean, D D Von Hoff, M Reni, et al.
European Urology|September 10, 2020
Apalutamide and Overall Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2010
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsI E Smith, J-Y Pierga, L Biganzoli, et al.
The Lancet. Oncology|September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trialCora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
JAMA Oncology|June 4, 2019
Factors Associated With Age Disparities Among Cancer Clinical Trial ParticipantsEthan B Ludmir, Walker Mainwaring, Timothy A Lin, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
Pageof 47

Showing results (431-440 of 465) with videos related to

Sort By:
Pageof 47
The Oncologist|April 10, 2020
Exclusion of Men from Randomized Phase III Breast Cancer Clinical TrialsKelsey L Corrigan, Walker Mainwaring, Austin B Miller, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 7, 2015
A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancerRebecca L Prue, Frank Vari, Kristen J Radford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerE G Chiorean, D D Von Hoff, M Reni, et al.
European Urology|September 10, 2020
Apalutamide and Overall Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2010
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsI E Smith, J-Y Pierga, L Biganzoli, et al.
The Lancet. Oncology|September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trialCora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
JAMA Oncology|June 4, 2019
Factors Associated With Age Disparities Among Cancer Clinical Trial ParticipantsEthan B Ludmir, Walker Mainwaring, Timothy A Lin, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
Pageof 47